PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER

PHII 三甲平联合吉西他滨治疗胆管和胆囊腺癌

• 批准号: 7378395
• 负责人: SCOTT H WADLER
• 金额: $ 2.84万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378395
• 关键词: PHII; TRIAPINE; GEMCITABINE; ADENOCARCINOMA; BILIARY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives are to: determine the objective response rates for the combination of triapine and gemcitabine in patients with primary tumors of the biliary ducts and gall bladder; assess the toxicities and recovery from toxicities for patients with biliary duct and gall baldder tumors treated with the combination of triapine and gemcitabine; and determine the survival and progression free survival of patients with biliary and gall bladder tumors treated with combination of triapine and gemcitabine.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。主要目标是：确定胆道和胆囊原发性肿瘤患者中三角洲和吉西他滨组合的客观反应率；评估胆道管和胆囊肿瘤患者的毒性和从毒性中恢复，这些患者与三角洲和吉西他滨的组合治疗；并确定胆汁和胆囊肿瘤患者的生存和进展无生存期，这些肿瘤与三角洲和吉西他滨组合治疗。